Smart-Money SignalDistribution · 41/100— Insiders are net sellers over 90 days (-$11.5M, 36 sales vs 12 buys)
Revenue$7.8B
Net Income-$10.5B
EPS$-6.82
Market Cap$182.1B
Price Performance
Historical data including institutional events
Company Profile
D
Daniel O'Day
CEO & Executive Director
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
